Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target

Compare

1,658 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ARWR Analyst Ratings

Moderate Buy

8 Buy

3 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Arrowhead

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ARWR Stock 12 Month Forecast

Average Price Target

$82.00

▲(18.27% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Arrowhead Pharmaceuticals in the last 3 months. The average price target is $82.00 with a high forecast of $110.00 and a low forecast of $35.00. The average price target represents a 18.27% change from the last price of $69.33.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","36":"$36","61":"$61","86":"$86","111":"$111"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$82.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,36,61,86,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.39,69.74461538461539,73.09923076923077,76.45384615384616,79.80846153846154,83.16307692307693,86.5176923076923,89.87230769230769,93.22692307692307,96.58153846153846,99.93615384615384,103.29076923076923,106.64538461538461,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.39,67.59076923076923,68.79153846153847,69.99230769230769,71.19307692307693,72.39384615384616,73.59461538461538,74.79538461538462,75.99615384615385,77.19692307692307,78.39769230769231,79.59846153846154,80.79923076923077,{"y":82,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.39,63.97538461538461,61.56076923076923,59.146153846153844,56.73153846153846,54.316923076923075,51.90230769230769,49.487692307692306,47.073076923076925,44.65846153846154,42.24384615384615,39.82923076923077,37.41461538461538,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.205,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.04,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.09,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.68,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.39,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.25,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.39,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$110.00

Average Price Target$82.00

Lowest Price Target$35.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

$85→$100

Buy

44.24%

Upside

Reiterated

01/22/26

Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (NASDAQ: BLTE), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Alector (NASDAQ: ALEC)

Madison Elsaadi

B. Riley Securities

$61→$101

Buy

45.68%

Upside

Reiterated

01/22/26

Arrowhead price target raised to $101 from $61 at B. RileyArrowhead price target raised to $101 from $61 at B. Riley

Edward Tenthoff

Piper Sandler

$100→$110

Buy

58.66%

Upside

Reiterated

01/13/26

Piper Sandler Remains a Buy on Arrowhead Pharmaceuticals (ARWR)

Andrea Newkirk

Goldman Sachs

$50→$85

Hold

22.60%

Upside

Reiterated

01/07/26

Arrowhead Pharmaceuticals (ARWR) Gets a Hold from Goldman Sachs

Keay Nakae

Chardan Capital

$60→$80

Buy

15.39%

Upside

Reiterated

01/07/26

Arrowhead price target raised to $80 from $60 at ChardanArrowhead price target raised to $80 from $60 at Chardan

Michael Ulz

Morgan Stanley

$48→$81

Hold

16.83%

Upside

Reiterated

01/07/26

Arrowhead price target raised to $81 from $48 at Morgan StanleyArrowhead price target raised to $81 from $48 at Morgan Stanley

William Pickering

Bernstein

$35

Hold

-49.52%

Downside

Reiterated

12/31/25

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Evolus (NASDAQ: EOLS)

Luca Issi

RBC Capital

$52→$80

Buy

15.39%

Upside

Reiterated

12/11/25

RBC Capital Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)

Jason Gerberry

Bank of America Securities

$62→$81

Buy

16.83%

Upside

Reiterated

12/08/25

Bank of America Securities Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$67

Buy

-3.36%

Downside

Reiterated

12/05/25

Arrowhead Pharmaceuticals (ARWR) Receives a Buy from Jefferies

Joseph Thome

TD Cowen

Buy

―

Reiterated

11/26/25

Arrowhead Pharmaceuticals: Promising Growth with Redemplo Launch and Strategic Developments in Obesity Treatments

Mani Foroohar

Leerink Partners

$21→$23

Hold

-66.83%

Downside

Reiterated

09/04/25

Cautious Optimism: Hold Rating for Arrowhead Pharmaceuticals Amid Novartis Collaboration and Balance Sheet Concerns

David Lebowitz

Citi

$27.8→$17

Hold

-75.48%

Downside

Reiterated

09/03/25

Hold Rating on Arrowhead Pharmaceuticals Amid Strategic Partnership and Market Competition

Eliana Merle

Barclays

$63→$12

Hold

-82.69%

Downside

Downgraded

07/21/25

UBS downgrades Arrowhead Pharmaceuticals (ARWR) to a Hold

Prakhar Agrawal

Cantor Fitzgerald

Buy

―

Reiterated

05/13/25

Cantor Fitzgerald reiterates Overweight Rating on Arrowhead Pharma (ARWR)Cantor Fitzgerald analyst Elemer Piros reiterated an Overweight rating on Arrowhead Pharma (NASDAQ: ARWR).

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

$85→$100

Buy

44.24%

Upside

Reiterated

01/22/26

Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (NASDAQ: BLTE), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Alector (NASDAQ: ALEC)

Madison Elsaadi

B. Riley Securities

$61→$101

Buy

45.68%

Upside

Reiterated

01/22/26

Arrowhead price target raised to $101 from $61 at B. RileyArrowhead price target raised to $101 from $61 at B. Riley

Edward Tenthoff

Piper Sandler

$100→$110

Buy

58.66%

Upside

Reiterated

01/13/26

Piper Sandler Remains a Buy on Arrowhead Pharmaceuticals (ARWR)

Andrea Newkirk

Goldman Sachs

$50→$85

Hold

22.60%

Upside

Reiterated

01/07/26

Arrowhead Pharmaceuticals (ARWR) Gets a Hold from Goldman Sachs

Keay Nakae

Chardan Capital

$60→$80

Buy

15.39%

Upside

Reiterated

01/07/26

Arrowhead price target raised to $80 from $60 at ChardanArrowhead price target raised to $80 from $60 at Chardan

Michael Ulz

Morgan Stanley

$48→$81

Hold

16.83%

Upside

Reiterated

01/07/26

Arrowhead price target raised to $81 from $48 at Morgan StanleyArrowhead price target raised to $81 from $48 at Morgan Stanley

William Pickering

Bernstein

$35

Hold

-49.52%

Downside

Reiterated

12/31/25

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Evolus (NASDAQ: EOLS)

Luca Issi

RBC Capital

$52→$80

Buy

15.39%

Upside

Reiterated

12/11/25

RBC Capital Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)

Jason Gerberry

Bank of America Securities

$62→$81

Buy

16.83%

Upside

Reiterated

12/08/25

Bank of America Securities Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$67

Buy

-3.36%

Downside

Reiterated

12/05/25

Arrowhead Pharmaceuticals (ARWR) Receives a Buy from Jefferies

Joseph Thome

TD Cowen

Buy

―

Reiterated

11/26/25

Arrowhead Pharmaceuticals: Promising Growth with Redemplo Launch and Strategic Developments in Obesity Treatments

Mani Foroohar

Leerink Partners

$21→$23

Hold

-66.83%

Downside

Reiterated

09/04/25

Cautious Optimism: Hold Rating for Arrowhead Pharmaceuticals Amid Novartis Collaboration and Balance Sheet Concerns

David Lebowitz

Citi

$27.8→$17

Hold

-75.48%

Downside

Reiterated

09/03/25

Hold Rating on Arrowhead Pharmaceuticals Amid Strategic Partnership and Market Competition

Eliana Merle

Barclays

$63→$12

Hold

-82.69%

Downside

Downgraded

07/21/25

UBS downgrades Arrowhead Pharmaceuticals (ARWR) to a Hold

Prakhar Agrawal

Cantor Fitzgerald

Buy

―

Reiterated

05/13/25

Cantor Fitzgerald reiterates Overweight Rating on Arrowhead Pharma (ARWR)Cantor Fitzgerald analyst Elemer Piros reiterated an Overweight rating on Arrowhead Pharma (NASDAQ: ARWR).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arrowhead Pharmaceuticals

3 Months

xxx

Success Rate

15/26 ratings generated profit

Average Return

+24.18%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.69% of your transactions generating a profit, with an average return of +24.18% per trade.

1 Year

Patrick TrucchioH.C. Wainwright

Success Rate

15/26 ratings generated profit

Average Return

+93.17%

reiterated a buy rating 12 days ago

Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 57.69% of your transactions generating a profit, with an average return of +93.17% per trade.

2 Years

xxx

Success Rate

14/14 ratings generated profit

Average Return

+167.91%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +167.91% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARWR Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ARWR has received 27 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. ARWR average Analyst price target in the past 3 months is 82.00.

Each month's total comprises the sum of three months' worth of ratings.

ARWR Financial Forecast

ARWR Earnings Forecast

Next quarter’s earnings estimate for ARWR is $0.04 with a range of -$1.37 to $1.63. The previous quarter’s EPS was -$0.11. ARWR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ARWR has Performed in-line its overall industry.

ARWR Sales Forecast

Next quarter’s sales forecast for ARWR is $213.94M with a range of $9.00M to $425.29M. The previous quarter’s sales results were $256.47M. ARWR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.06% of the time in the same period. In the last calendar year ARWR has Performed in-line its overall industry.

ARWR Stock Forecast FAQ

What is ARWR’s average 12-month price target, according to analysts?

Based on analyst ratings, Arrowhead Pharmaceuticals’s 12-month average price target is 82.00.

What is ARWR’s upside potential, based on the analysts’ average price target?

Arrowhead Pharmaceuticals has 18.27% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ARWR a Buy, Sell or Hold?

Arrowhead Pharmaceuticals has a consensus rating of Moderate Buy which is based on 8 buy ratings, 3 hold ratings and 0 sell ratings.

What is Arrowhead Pharmaceuticals’s price target?

The average price target for Arrowhead Pharmaceuticals is 82.00. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $110.00 ,the lowest forecast is $35.00. The average price target represents 18.27% Increase from the current price of $69.33.

What do analysts say about Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of ARWR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target

ARWR Analyst Ratings

ARWR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Arrowhead Pharmaceuticals

ARWR Analyst Recommendation Trends

ARWR Financial Forecast

ARWR Earnings Forecast

ARWR Sales Forecast

ARWR Stock Forecast FAQ

Detailed List of Analyst Forecasts